RedHill Biopharma (RDHL) Interest & Investment Income (2012 - 2023)

RedHill Biopharma (RDHL) has 12 years of Interest & Investment Income data on file, last reported at $7.1 million in Q2 2023.

• On a quarterly basis, Interest & Investment Income rose 326.9% year-over-year to $7.1 million in Q2 2023; TTM through Jun 2023 was $40.6 million, a 2284.89% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, down 84.21% from the prior year.
• Interest & Investment Income for Q2 2023 stood at $7.1 million, down from $21.6 million in the prior quarter.
• Over the last five years, Interest & Investment Income for RDHL reached as high as $21.6 million in Q1 2023 and fell as low as -$214000.0 in Q1 2020.
• Historically, Interest & Investment Income has averaged $2.5 million across 5 years, with a median of $139000.0 in 2019.
• Across the five-year window, Interest & Investment Income plunged 157.22% in 2020 and jumped 215720.0% in 2023, its largest moves.
• Year by year, Interest & Investment Income stood at $260000.0 in 2019, then tumbled by 126.54% to -$69000.0 in 2020, then jumped by 117.39% to $12000.0 in 2021, then soared by 72400.0% to $8.7 million in 2022, then slipped by 18.45% to $7.1 million in 2023.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $7.1 million in Q2 2023, $21.6 million in Q1 2023, and $8.7 million in Q4 2022.